Abstract
BackgroundUrine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer.MethodsSerum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology.ResultsThe median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ?11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R?=?2.1, 95% CI, 1.1 to 4.4).ConclusionsOur results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.
Highlights
Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer
Measurement of Matrix metalloproteinase-7 (MMP-7) serum level We previously developed and validated a homogeneous sandwich fluoroimmunoassay [18] based on the time resolved amplified cryptate emission (TRACE) technology
A total of 56 patients who received a diagnosis of urothelial tumor between January 1995 and November 2004 were enrolled in this study
Summary
Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. We assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer. Approximately 75% of bladder cancers are non-muscle invasive [pTa, pT1, carcinoma in situ (CIS)], 25% are muscle-invasive (pT2-pT4) and 5% are metastatic (N1-3 or M1) [2]. The standard treatment includes transurethral resection of the bladder tumor (TURBT) and intravesical chemotherapy or immunotherapy for superficial predict the tumor biological behavior or to guide treatment choices. Urine markers have been studied extensively but cannot be standardized due to diuresis variations, and blood prognostic markers for Sex M F AGE Median (Range) Histology Urothelial Other Unknown TNM at diagnosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
